associated with a higher rate of mortality in comparison with favipiravir use. In conclusion,
uncorrected proof patients with hematological malignancy infected with SARS-CoV-2 have an increased risk of
Millions of people have been infected with severe acute respiratory syndrome coronavirus-2
(SARS-Cov-2) worldwide. Comorbidities like diabetes mellitus, hypertension, chronic renal
failure as well as older age have been identified as risk factors for the severity of COVID-19(1-4).
Cancer patients also are found to be more vulnerable to SARS-CoV-2 infection than healthy
population in studies that mostly included solid malignancies (5-7). The increased risk of respiratory tract viral infections in hematological malignancy and hematopoietic stem cell transplantation(HSCT) patients has been previously reported (8,9). Either the underlying diagnosis or the treatments may influence the humoral and cellular immune function negatively, and result in a poor outcome. The clinical characteristics and risk factors that may be predictive for severity or mortality of COVID-19 in hematological
On behalf of the Turkish Society of Hematology, Infectious Complications and Supportive Care
Working Party, we retrospectively collected data from 25 centers in Turkey from March to
November 2020. The study was approved by both the Turkish Ministry of Health and the
Ethical Committee of Istanbul University- Cerrahpaşa School of Medicine(22-Sep2020/80350) and also locally by the participating centers.
Patients were included in the study according to the following criteria; a)if they had SARSCoV-2 PCR positivity via nasal swabs b) if they had negative PCR results but symptoms
related with SARS-CoV-2 with highly suggestive thoracal computerized tomography (CT)
findings. Patients who were followed up as both outpatient and inpatient for COVID were
eligible for the study Forms for data collection were e-mailed to participating centers.
Diagnosis and status of primary disease, treatment schedules for hematological malignancies,
time from the last treatment, life expectancy related to the hematological disease have been
recorded. Data regarding symptoms related to SARS-CoV-2 infection, hospitalization and
oxygen requirement, severity, complications organ involvement, laboratory parameters on
admission and treatments given for COVID 19 have also been investigated. Co-morbidities
were defined as diabetes mellitus, hypertension, chronic renal failure, chronic obstructive
pulmonary disease, cardiovascular disease, or pre-existing solid malignancy diagnosis were